Amgen, Inc.’s Imdelltra (tarlatamab) for extensive-stage small cell lung cancer (ES-SCLC) is one of only two bispecific T-cell engagers (BiTEs) approved in the US to treat solid tumors. As additional DLL3-targeting BiTEs near the market, those drugs may benefit from doctors’ earlier experience learning to manage adverse events for BiTEs and other T-cell recruiters – chiefly cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)
Key Takeaways
-
Data for DLL3-targeting bispecific T-cell engagers (BiTEs) – Amgen’s Imdelltra, Boehringer’s obrixtamig and Merck/Daiichi’s MK-6070 – show efficacy that may best the standard of care in small-cell lung cancer but with adverse events previously uncommon with solid tumor drugs.
Clinical trial results were presented at the recent World Conference on Lung Cancer (WCLC) for Imdelltra and two other DLL3...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
